Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study.

被引：95
|
作者：
Llovet, Josep M.
Kudo, Masatoshi
Cheng, Ann-Lii
Finn, Richard S.
Galle, Peter R.
Kaneko, Shuichi
Meyer, Tim
Qin, Shukui
Dutcus, Corina E.
Chen, Erluo
Dubrovsky, Leonid
Zhu, Andrew X.
机构：
[1] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[2] Kindai Univ, Sch Med, Osakasayama, Japan
[3] Natl Taiwan Univ Hosp, Ctr Canc, Taipei, Taiwan
[4] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[5] Johannes Gutenberg Univ Mainz, Med Ctr, Mainz, Germany
[6] Kanazawa Univ Hosp, Kanazawa, Ishikawa, Japan
[7] UCL, Inst Canc, London, England
[8] Peoples Liberat Army, Hosp 81, Nanjing, Jiangsu, Peoples R China
[9] Eisai Inc, Woodcliff Lake, NJ USA
[10] Merck & Co Inc, Kenilworth, NJ USA
[11] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.TPS4152
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4152
引用
收藏
页数：2
相关论文
共 50 条
  • [1] LEAP-002: phase 3 study of first-line lenvatinib plus pembrolizumab for patients with advanced hepatocellular carcinoma
    Llovet, Josep
    Kudo, Masatoshi
    Cheng, Ann-Lii
    Finn, Richard
    Galle, Peter
    Kaneko, Shuichi
    Meyer, Tim
    Qin, Shukui
    Dutcus, Corina
    Chen, Erluo
    Dubrovsky, Leonid
    Siegel, Abby
    Zhu, Andrew
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [2] Pembrolizumab (pembro) plus lenvatinib (len) for first-line treatment of patients (pts) with advanced melanoma: Phase III LEAP-003 study
    Eggermont, A. M. M.
    Carlino, M. S.
    Hauschild, A.
    Ascierto, P. A.
    Arance, A.
    Daud, A.
    O'Day, S. J.
    Taylor, M. H.
    Smith, A.
    Rodgers, A.
    Moreno, B. Homet
    Diede, S. J.
    Kluger, H.
    ANNALS OF ONCOLOGY, 2019, 30
  • [3] Health-related quality of life (HRQoL) impact of lenvatinib (len) plus pembrolizumab (pembro) versus len plus placebo (pbo) as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC): Phase 3 LEAP-002 study.
    Llovet, Josep M.
    Kudo, Masatoshi
    Merle, Philippe
    Meyer, Tim
    Qin, Shukui
    Ikeda, Masafumi
    Xu, Ruocai
    Edeline, Julien
    Ryoo, Baek-Yeol
    Ren, Zhenggang
    Cheng, Ann-Lii
    Galle, Peter R.
    Kaneko, Shuichi
    Kumada, Hiromitsu
    Kamble, Shital
    Norquist, Josephine M.
    Mody, Kalgi
    Dubrovsky, Leonid
    Siegel, Abby B.
    Finn, Richard S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 506 - 506
  • [4] Lenvatinib plus pembrolizumab versus lenvatinib alone as first-line therapy for advanced hepatocellular carcinoma: Longer-term efficacy and safety results from the phase 3 LEAP-002 study.
    Kudo, Masatoshi
    Finn, Richard S.
    Merle, Philippe
    Meyer, Tim
    Qin, Shukui
    Ikeda, Masafumi
    Xu, Ruocai
    Edeline, Julien
    Ryoo, Baek-Yeol
    Ren, Zhenggang
    Cheng, Ann-Lii
    Galle, Peter R.
    Kaneko, Shuichi
    Kumada, Hiromitsu
    Wang, Anran
    Mody, Kalgi
    Dubrovsky, Leonid
    Siegel, Abby B.
    Llovet, Josep M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 482 - 482
  • [5] Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)
    Finn, R. S.
    Kudo, M.
    Merle, P.
    Meyer, T.
    Qin, S.
    Ikeda, M.
    Xu, R.
    Edeline, J.
    Ryoo, B-Y.
    Ren, Z.
    Cheng, A-L.
    Galle, P. R.
    Kaneko, S.
    Kumada, H.
    Wang, A.
    Mody, K.
    Dubrovsky, L.
    Siegel, A. B.
    Llovet, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1401 - S1401
  • [6] Phase Ib study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC)
    El-Khoueiry, Anthony B.
    Kim, Richard D.
    Harris, William P.
    Sung, Max W.
    Waldschmidt, Dirk
    Iqbal, Syma
    Zhang, Xiaojing
    Nakajima, Keiko
    Galle, Peter R.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [7] Phase III study of first-line pembrolizumab (pembro) plus lenvatinib (len) in patients (pts) with advanced urothelial carcinoma (UC) ineligible for platinum-based chemotherapy: LEAP-011
    Loriot, Yohann
    Balar, Arjun Vasant
    De Wit, Ronald
    Garcia, Jorge A.
    Grivas, Petros
    Matsubara, Nobuaki
    Moreno, Blanca Homet
    Sbar, Eric
    Jia, Xieyang Calvin
    Dutcus, Corina E.
    Siefker-Radtke, Arlene O.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [8] Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002) a randomised, double-blind, phase 3 trial
    Llovet, Josep M.
    Kudo, Masatoshi
    Merle, Philippe
    Meyer, Tim
    Qin, Shukui
    Ikeda, Masafumi
    Xu, Ruocai
    Edeline, Julien
    Ryoo, Baek-Yeol
    Ren, Zhenggang
    Masi, Gianluca
    Kwiatkowski, Mariusz
    Lim, Ho Yeong
    Kim, Jee Hyun
    Breder, Valeriy
    Kumada, Hiromitsu
    Cheng, Ann-Lii
    Galle, Peter R.
    Kaneko, Shuichi
    Wang, Anran
    Mody, Kalgi
    Dutcus, Corina
    Dubrovsky, Leonid
    Siegel, Abby B.
    Finn, Richard S.
    LANCET ONCOLOGY, 2023, 24 (12): : 1399 - 1410
  • [9] Phase 1b study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC)
    Waldschmidt, D.
    El-Khoueir, A. B.
    Kim, R. D.
    Harris, W. P.
    Sung, M. W.
    Iqbal, S.
    Zhang, A.
    Nakajima, K.
    Galle, P. R.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 123 - 123
  • [10] Updated results of a phase Ib study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC)
    Galle, P. R.
    Kim, R. D.
    Sung, M. W.
    Harris, W. P.
    Waldschmidt, D.
    Cabrera, R.
    Mueller, U.
    Nakajima, K.
    Ishida, T.
    El-Khoueiry, A. B.
    ANNALS OF ONCOLOGY, 2020, 31 : S691 - S692
12345